Talk:Adverum Biotechnologies
| This is the talk page for discussing improvements to the Adverum Biotechnologies article. This is not a forum for general discussion of the article's subject. |
Article policies
|
| Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL |
 | This article is rated Stub-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||
| ||||||||||||||||||
Update Request to Adverum Bio
edit | This edit request by an editor with a conflict of interest has now been answered. |
- What I think should be changed: Key People in the box on the right:
- Why it should be changed: It is no longer accurate:
- References supporting the possible change (format using the "cite" button):
Update names for accuracy and remove names no longer listed on the website: [1] Laurent Fischer, M.D., Chief Executive officer Leone Patterson, President & Chief Financial Officer Peter Soparkar, J.D., Chief Legal Officer Angela Thedinga, MBA, MPH, Chief Technology Officer
SKM.SamBrown (talk) 20:45, 6 April 2021 (UTC) Suzanne Madore
Update Request to Adverum Bio
edit | Part of an edit requested by an editor with a conflict of interest has been implemented. Updated to include DME trial. Info on manufacturing facility is undue, promotional content with no secondary sources Stonkaments (talk) 19:30, 26 April 2021 (UTC) |
- What I think should be changed (include citations):
1. The pipeline listed needs to be updated [1] 2. Text in the first paragraph needs to be updated ...is a clinical-stage gene therapy company headquartered in Redwood City, California with a GMP manufacturing facility in Durham, North Carolina [2]. The company is targeting unmet medical needs for serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, designed as a one-time, intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD).[3] and diabetic macular edema (DME) [3].
3. Update to last paragraph: ADVM-022 is currently being evaluated in a Phase 2 trial for DME called INFINITY (NCT04418427).[4]
- Why it should be changed:
1. It has recently been updated [5] 2. Language has been updated for specificity and legal requests. 3. This is a recent update for ADVM-022
SKM.SamBrown (talk) 13:49, 26 April 2021 (UTC)Suzanne Madore, Sam Brown Communications, agency of record for Adverum Bio
SKM.SamBrown (talk) 13:49, 26 April 2021 (UTC)
References
- ^ https://adverum.com/pipeline/
- ^ https://investors.adverum.com/news-releases/news-release-details/adverum-biotechnologies-announces-new-gmp-gene-therapy
- ^ https://clinicaltrials.gov/ct2/show/NCT04418427?cond=ADVM-022&draw=2&rank=1
- ^ https://clinicaltrials.gov/ct2/show/NCT04418427?cond=ADVM-022&draw=2&rank=1
- ^ https://adverum.com/pipeline/
- Edited to include mention of DME. Also edited the information for conciseness and clarity, as some of the details weren't suitable for the lead section. Stonkaments (talk) 19:34, 26 April 2021 (UTC)